Skip to main content

Advertisement

Table 2 Summary of the reported CRP change and the sponsors for the studies included in the meta-analysis on the short-term effect of fenofibrate on CRP

From: Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials

Index Country Study Name Baseline CRP (mg/L)† Post-treatment CRP (mg/L)† Sponsor
1 Korea Kim et al., 2006 [40] 1.74 ± 1.74 1.54 ± 1.66 No mention
2 UK Fegan et al., 2005 [17] 3.27 ± 1.71 4.03 ± 3.13 Bayer pharmaceuticals
3 Poland Undas et al. 2005 [41] 2.33 ± 2.81 1.45 ± 1.41 Polish committee for scientific research and Merck Sharp & Dohme & Fournier Laboratories
4 Slovenia Sebestjen et al., 2004 [42] 1.60 (1.10, 3.30)* 1.10 (0.70, 2.70)* No mention
5 Taiwan Wang et al.,2003 [43] 1.70 (0.90, 2.30)* 1.30 (0.70, 2.00)* National Taiwan University Hospital, National Science Council and the Academia Sinica (China)
6 Korea Wi et al., 2010 [15] 1.20 (0.43, 3.86)* 0.90 (0.30, 4.86)* Ministry of Health and welfare (Korea), R&BD program (Korea) and Cardiovascular Research Center (Korea)
7 Poland Krysiak et al., 2010 [44] 2.4 ± 1.56 1.20 ± 0.78 Committee of Scientific Research
8 Poland Krysiak et al., 2010 [44] 1.70 ± 0.87 0.90 ± 0.44 Committee of Scientific Research
9 USA-MI Rosenson et al., 2010 [45] 2.60 (1.40, 3.10)* 1.90 (1.10, 2.60)* Abbott Laboratories
10 USA-TX Belfort et al. 2010 [46] 6.50 ± 6.00 3.60 ± 3.60 Veterans Admission Research Career development award, Howard Hughes Medical Institute, the Veterans Affairs Medical Research Fund and the National Center for Research Resources
11 Poland Pruski et al., 2009 [24] 2.8 ± 1.10 1.90 ± 2.19 Medical University of Silesia
12 USA-UT Muhlestein et al., 2006 [13] 1.99** 1.45** No mention
13 Poland Okopien et al., 2006 [32] 2.6 ± 1.27 1.95 ± 1.27 Medical University of Silesia
14 Canada Hogue et al., 2008 [18] 2.97 ± 3.29 2.86 ± 3.58 Pfizer
  1. †Figures reported as mean ± standard deviation; * Figures reported as median (25th quartile, 75th quartile); **Only medians reported.